Gapping up
In reaction to strong earnings/guidance:
- TITN +21%, TLYS +15.8%, SIG +13%, MESO +12.2%, GES +9.5%, CIEN +7.7%, SMTC +7.2%, PERY +5.3%, GMS +3.4%
Other news:
- MNOV +8.5% (modestly higher after noting its SPRINT-MS Phase 2b trial of MN-166 (ibudilast) in progressive multiple sclerosis results were published in NEJM)
- INSY +7.4% (granted Fast Track designation by the FDA for epinephrine nasal spray as an investigational treatment for anaphylaxis)
- TRNC +3.5% (following Nieman Lab report that Donerail Group has secured financing for a takeover bid)
- VGR +2.9% (indicated higher after declaring unchanged $0.40/share quarterly dividend and granting stockholders additional 5% annual stock dividend-also unchanged from prior year)
- VSTM +1.5% (appoints Robert Gagnon CFO, effective August 28)
Analyst comments:
- TOCA +9.7% (initiated with a Buy at Chardan Capital Markets)
- ARLO +3.7% (upgraded to Buy from Neutral at Guggenheim)
- GCO +1.7% (upgraded to Buy at Pivotal Research Group)
- TNDM +1.6% (initiated with a Buy at Berenberg)
- NTNX +1.4% (upgraded to Neutral from Underweight at JP Morgan)
![]()